Clinical Trial Detail

NCT ID NCT04176848
Title CFI-400945 and Durvalumab in Patients With Advanced Triple Negative Breast Cancer
Recruitment Recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors Canadian Cancer Trials Group
Indications

triple-receptor negative breast cancer

Her2-receptor negative breast cancer

Therapies

CFI-400945 + Durvalumab

Age Groups: adult senior

No variant requirements are available.